

Internal identification field:

Date / PO No. / pharmacotherapeutic follow-up dossier (PTFD) No.

Administrative identification field

Pharmacy: Name, company name, address, Tel., fax, e-mail,...

Healthcare professional(s): CAG... Valérie, GP; 4599999999 adresse, Tel., fax, e-mail,...

Patient: Name, Valérie, adresse, Tel., e-mail,...

Patient profile:

Disease: Common migraine – Condition deduced from history of previous drugs dispensed-
(Date)

Biometrics: 66 years old; 172 cm; 82 kg; Body surface area = 1.952m²; BMI = 27.72

Nature of the problem:

ZITHROMAX[®] and Dihydroergotamine Sandoz[®]

- Critical point,
- Interaction,
- Clinically significant interaction.

Pharmaceutical arguments

Argument: Concomitant intake of **Dihydroergotamine Sandoz[®]** prescribed previously. Contraindication between azithromycin and DHE due to inhibition of the hepatic metabolism of DHE by the macrolide, leading to a risk of ergotism with the possibility of necrosis of the extremities.

Proposal: **Change from ZITHROMAX[®] to ROVAMYCINE[®], a macrolide presenting the same spectrum of activity without the risks of interaction.**

Decision:

- Therapeutic equivalent**

ROVAMYCINE[®] 3 MIU

1 tablet twice daily

Reference: BCB (month year)

Implementation of the decision:

Notification:

- Pharmaceutical Opinion not notified**
- Patient informed

Signing pharmacist:

- Dr Zed Titular pharmacist 67865A

This Pharmaceutical Opinion format was produced in accordance with the proposal in the [technical specifications](#). IT service companies are free to offer any other format on condition that it follows the order of the required information.